Months Later, Ex-Allergan CEO Is Still Going After Ackman's Pershing Square

After his bitter, 8½-month battle with Valeant and activist hedge fund Pershing Square last year, former Allergan chief David Pyott is not going quietly.

"I've visited many members of Congress, doing my best to ensure whatever oversight is possible," Pyott said at a hearing Thursday by the Senate Permanent Subcommittee on Investigations on the U.S. tax code.

Allergan said its U.S. domicile and higher tax code gave it $9 billion more in value to a foreign purchaser; Canada-based Valeant has a tax rate of less than 10 percent.

Help employers find you! Check out all the jobs and post your resume.

Back to news